10.00
Atara Biotherapeutics Inc stock is traded at $10.00, with a volume of 112.20K.
It is up +2.99% in the last 24 hours and up +24.69% over the past month.
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA188, and ATA3219 (CAR T Platform).
See More
Previous Close:
$9.71
Open:
$9.8
24h Volume:
112.20K
Relative Volume:
2.06
Market Cap:
$59.61M
Revenue:
$100.44M
Net Income/Loss:
$-133.16M
P/E Ratio:
-0.3882
EPS:
-25.76
Net Cash Flow:
$-94.85M
1W Performance:
+8.34%
1M Performance:
+24.69%
6M Performance:
+52.21%
1Y Performance:
-4.81%
Atara Biotherapeutics Inc Stock (ATRA) Company Profile
Name
Atara Biotherapeutics Inc
Sector
Industry
Phone
805-623-4211
Address
1280 RANCHO CONEJO BLVD, THOUSAND OAKS, CA
Compare ATRA with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
ATRA
Atara Biotherapeutics Inc
|
10.00 | 55.02M | 100.44M | -133.16M | -94.85M | -25.76 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
459.81 | 120.40B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
542.52 | 61.30B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
320.53 | 41.06B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
564.59 | 34.29B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
294.55 | 27.09B | 3.81B | -644.79M | -669.77M | -6.24 |
Atara Biotherapeutics Inc Stock (ATRA) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Nov-09-23 | Downgrade | Evercore ISI | Outperform → In-line |
Nov-09-23 | Downgrade | H.C. Wainwright | Buy → Neutral |
Nov-09-23 | Downgrade | Mizuho | Buy → Neutral |
Jul-20-22 | Downgrade | Citigroup | Neutral → Sell |
Jul-13-22 | Downgrade | JP Morgan | Overweight → Neutral |
Jul-13-22 | Downgrade | Stifel | Buy → Hold |
May-10-22 | Downgrade | Citigroup | Buy → Neutral |
May-13-21 | Upgrade | JP Morgan | Neutral → Overweight |
Dec-09-20 | Downgrade | Citigroup | Buy → Neutral |
Dec-08-20 | Reiterated | H.C. Wainwright | Buy |
Nov-10-20 | Reiterated | H.C. Wainwright | Buy |
Jun-30-20 | Initiated | Evercore ISI | Outperform |
Jun-15-20 | Initiated | H.C. Wainwright | Buy |
Apr-23-20 | Upgrade | Citigroup | Neutral → Buy |
Nov-08-19 | Downgrade | JP Morgan | Overweight → Neutral |
Sep-27-19 | Downgrade | Goldman | Neutral → Sell |
Sep-16-19 | Downgrade | Jefferies | Buy → Hold |
Jun-04-19 | Upgrade | Citigroup | Sell → Neutral |
May-30-19 | Initiated | ROTH Capital | Buy |
May-23-19 | Initiated | Stifel | Buy |
Jan-23-19 | Initiated | Mizuho | Buy |
Apr-10-18 | Initiated | JP Morgan | Overweight |
Mar-16-18 | Initiated | Guggenheim | Neutral |
Mar-05-18 | Reiterated | Jefferies | Buy |
Feb-28-18 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
Feb-15-18 | Downgrade | Citigroup | Neutral → Sell |
Jan-03-18 | Upgrade | Citigroup | Sell → Neutral |
Oct-06-17 | Resumed | Goldman | Neutral |
View All
Atara Biotherapeutics Inc Stock (ATRA) Latest News
Is Atara Biotherapeutics Inc. a good long term investmentTriple-digit wealth increases - Autocar Professional
What drives Atara Biotherapeutics Inc. stock priceOutstanding capital appreciation - Jammu Links News
What analysts say about Atara Biotherapeutics Inc. stockUnprecedented profits - Jammu Links News
How Atara Biotherapeutics Inc. stock performs during market volatilityDaily Breakout Picks - Newser
Why Atara Biotherapeutics Inc. stock attracts strong analyst attentionFree Discussion Group - Newser
What makes Atara Biotherapeutics Inc. stock price move sharplyFree Consultation - Newser
Major FDA Development: Pierre Fabre Assumes Control of Atara's EBV Cell Therapy Program After BLA Resubmission - Stock Titan
Atara Biotherapeutics Resubmits BLA for Tab-cel to FDA - TipRanks
Atara Biotherapeutics Provides Regulatory and Business Updates on Tabelecleucel (Tab-cel®) | ATRA Stock News - GuruFocus
Atara Biotherapeutics provides regulatory and business updates on tabelecleucel (tab-cel) - MarketScreener
Atara resubmits tabelecleucel BLA to FDA for EBV-positive PTLD By Investing.com - Investing.com Canada
Atara Biotherapeutics Provides Regulatory and Business Updates on Tabelecleucel (Tab-cel - Business Wire
(ATRA) Technical Data - news.stocktradersdaily.com
We Might See A Profit From Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Soon - simplywall.st
Atara Biotherapeutics, Inc.(NasdaqGS: ATRA) added to Russell Microcap Growth Index - MarketScreener
Layoff Tracker: Gilead Cuts 36 Employees in California - BioSpace
Atara Biotherapeutics Holds Annual Stockholders Meeting - TipRanks
Long Term Trading Analysis for (ATRA) - news.stocktradersdaily.com
Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Given Consensus Rating of “Moderate Buy” by Analysts - Defense World
Northern Trust Corp Purchases New Position in Atara Biotherapeutics, Inc. (NASDAQ:ATRA) - Defense World
Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Short Interest Update - Defense World
Bank of America Corp DE Acquires 1,543 Shares of Atara Biotherapeutics, Inc. (NASDAQ:ATRA) - Defense World
Redmile Group, LLC's Strategic Acquisition in Atara Biotherapeutics Inc - GuruFocus
Here's Why You Should Consider Buying Atara Biotherapeutics Stock - Barchart.com
Biotech Pioneer Pascal Touchon Joins CDR-Life Board: Former Atara CEO to Drive T Cell Platform Innovation - Stock Titan
(ATRA) Trading Advice - news.stocktradersdaily.com
Atara Biotherapeutics (NASDAQ:ATRA) & Turnstone Biologics (NASDAQ:TSBX) Financial Analysis - Defense World
Top Executives at Atara Biotherapeutics Make Significant Stock Sales! - TipRanks
Atara Biotherapeutics Executives Sell Shares for Tax Obligations - TradingView
Citadel Advisors LLC Has $3.56 Million Position in Atara Biotherapeutics, Inc. (NASDAQ:ATRA) - Defense World
FDA Delivers Blow to ImmunityBio - Los Angeles Business Journal
Atara Biotherapeutics Appoints James Huang and Nachi Subramanian to Board of Directors - BioSpace
Atara Biotherapeutics (ATRA) Expands Board Following $16 Million Offering | ATRA Stock News - GuruFocus
Atara Biotherapeutics Appoints James Huang and Nachi Subramanian to Board of Directors | ATRA Stock News - GuruFocus
Atara Biotherapeutics Reports Strong Q1 2025 Results - TipRanks
(ATRA) Investment Analysis and Advice - news.stocktradersdaily.com
Atara Biotherapeutics Announces $16M Stock Offering - TipRanks
Atara Biotherapeutics First Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
Atara Biotherapeutics: Q1 Earnings Snapshot - CT Insider
Atara Biotherapeutics sets stock and warrant offering prices By Investing.com - Investing.com India
Atara Biotherapeutics Inc Stock (ATRA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):